Omar Khwaja is Chief Medical Officer and Head of Research and Development at Voyager Therapeutics, a biotechnology company in Cambridge, Massachusetts developing gene therapies for severe neurological disorders. Prior to joining Voyager, Omar was Global Head of Rare Diseases and Global Head of Neuroscience Translational Medicine at Roche. Dr Khwaja is a pediatric neurologist and geneticist by training. Before moving to industry, Omar was on the faculty of Harvard Medical School and an attending physician in neurology at Boston Children’s Hospital. He is a member of the Royal College of Physicians and the Royal College of Paediatrics and Child Health. Omar received his medical degree and PhD from the University of Cambridge and trained in pediatrics and genetics in London and Melbourne. Omar completed neurology residency in the Harvard Child Neurology Program and was Chief Resident at Boston Children’s Hospital where he also did a fellowship in critical care neurology and fetal -neonatal neurology. Omar serves on the Boards of Korro Bio as well as Pureos Bioventures. He is an honorary consultant paediatric neurologist at the Royal London Hospital as well as Chief Medical Officer of the SMA Foundation. Omar chairs the Scientific Advisory Board for this year’s CDKL5 Forum.